- Home
- BOLD vs HOWL Comparison
BOLD vs HOWL Comparison
Compare BOLD & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BOLD | HOWL |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.7M | 30.7M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BOLD | HOWL |
|---|---|---|
| Price | $1.13 | $0.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $4.00 | ★ $7.00 |
| AVG Volume (30 Days) | 57.3K | ★ 385.3K |
| Earning Date | 06-22-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.47 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.96 | $0.53 |
| 52 Week High | $1.78 | $2.23 |
Technical Indicators
Market Signals| Indicator | BOLD | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 46.09 | 68.87 |
| Support Level | $1.10 | $0.81 |
| Resistance Level | $1.19 | $1.03 |
| Average True Range (ATR) | 0.03 | 0.07 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 37.50 | 96.01 |
Price Performance
Historical ComparisonAbout BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.